Colleen F. Kelley

ORCID: 0000-0001-5611-0119
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV/AIDS Research and Interventions
  • HIV, Drug Use, Sexual Risk
  • HIV Research and Treatment
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • HIV/AIDS drug development and treatment
  • Sex work and related issues
  • Reproductive tract infections research
  • Adolescent Sexual and Reproductive Health
  • HIV-related health complications and treatments
  • Long-Term Effects of COVID-19
  • SARS-CoV-2 detection and testing
  • Syphilis Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • COVID-19 epidemiological studies
  • Asthma and respiratory diseases
  • Clostridium difficile and Clostridium perfringens research
  • Respiratory Support and Mechanisms
  • LGBTQ Health, Identity, and Policy
  • Animal Virus Infections Studies
  • Poxvirus research and outbreaks
  • Immunotherapy and Immune Responses
  • Cytomegalovirus and herpesvirus research
  • Dermatology and Skin Diseases
  • Pneumocystis jirovecii pneumonia detection and treatment

Emory University
2016-2025

Grady Memorial Hospital
2004-2025

Grady Health System
2019-2025

Infectious Diseases Society of America
2025

Association Clinique et Thérapeutique Infantile du Val de Marne
2024

HOPE Clinic
2016-2024

University of Washington
2024

University of California, San Francisco
2024

San Francisco General Hospital
2007-2024

Christ University
2024

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk COVID-19 disease protection. These immune markers measured at time second vaccination 4 weeks later, with values reported in standardized World Health Organization international units. All inversely associated directly efficacy. Vaccine postvaccination 50% neutralization titers 10, 100, 1000 had estimated efficacies 78% (95% confidence...

10.1126/science.abm3425 article EN Science 2022-01-06
Amarendra Pegu Sarah O’Connell Stephen D. Schmidt Sijy O’Dell Chloe Adrienna Talana and 95 more Lilin Lai Jim Albert Evan J. Anderson Hamilton Bennett Kizzmekia S. Corbett Britta Flach Lisa A. Jackson Brett Leav Julie E. Ledgerwood Catherine J. Luke Mat Makowski Martha Nason Paul C. Roberts Mario Roederer Paulina A. Rebolledo Christina A. Rostad Nadine Rouphael Wei Shi Lingshu Wang Alicia T. Widge Eun Sung Yang John H. Beigel Barney S. Graham John R. Mascola Mehul S. Suthar Adrian B. McDermott Nicole A. Doria‐Rose Jae Arega John H. Beigel Wendy Buchanan Mohammed Elsafy Binh Hoang Rebecca Lampley Aparna Kolhekar Hyung Il Koo Catherine J. Luke Mamodikoe Makhene Seema Nayak Rhonda Pikaart-Tautges Paul C. Roberts Janie Russell Elisa Sindall Jim Albert Pratap Kunwar Mat Makowski Evan J. Anderson Amer Bechnak Mary Bower Andrés Camacho-González Matthew H. Collins Ana Drobeniuc Venkata Viswanadh Edara Srilatha Edupuganti Katharine Floyd Theda Gibson Cassie M. Grimsley Ackerley Brandi Johnson Satoshi Kamidani Carol Kao Colleen F. Kelley Lilin Lai Hollie Macenczak Michele Paine McCullough Etza Peters Varun K. Phadke Paulina A. Rebolledo Christina A. Rostad Nadine Rouphael Erin M. Scherer Amy C Sherman Kathy Stephens Mehul S. Suthar Mehgan Teherani Jessica Traenkner Juton Winston İnci Yıldırım Lee Barr Joyce Benoit Barbara Carste Joe Choe Maya Dunstan Roxanne Erolin Jana ffitch Colin Fields Lisa A. Jackson Erika Kiniry Susan Lasicka Stella E. Lee M. Nguyen Stephanie Pimienta Janice Suyehira Michael M. Witte Hamilton Bennett Nedim Emil Altaras Andrea Carfı́

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, angiotensin-converting enzyme (ACE2)–competing antibodies elicited by messenger RNA (mRNA) vaccine mRNA-1273 7 months. Cross-reactive...

10.1126/science.abj4176 article EN cc-by Science 2021-08-12

Although antiretroviral therapy has the ability to fully restore a normal CD4(+) cell count (>500 cells/mm(3)) in most patients, it is not yet clear whether all patients can achieve normalization of their count, part because no study followed up for >7 years.Three hundred sixty-six from 5 clinical cohorts who maintained plasma human immunodeficiency virus (HIV) RNA level 1000 copies/mL at least 4 years after initiation were included. Changes evaluated using mixed-effects modeling,...

10.1086/597093 article EN Clinical Infectious Diseases 2009-02-04
Martin R. Gaudinski Katherine V. Houser Kaitlyn M. Morabito Zonghui Hu Galina V. Yamshchikov and 95 more Ro Shauna Rothwell Nina M. Berkowitz Floreliz Mendoza Jamie Saunders Laura Novik Cynthia S. Hendel LaSonji A. Holman Ingelise J. Gordon Josephine H. Cox Srilatha Edupuganti Monica A. McArthur Nadine Rouphael Kirsten E. Lyke Ginny E. Cummings Sandra Sitar Robert T. Bailer Bryant M. Foreman Katherine E. Burgomaster Rebecca S. Pelc David Gordon Christina R. DeMaso Kimberly A. Dowd Carolyn M. Laurençot Richard Schwartz John R. Mascola Barney S. Graham Theodore C. Pierson Julie E. Ledgerwood Grace Chen Sarah H. Plummer Pamela Costner Kathryn L. Zephir Joseph P. Casazza Abidemi Ola Milalynn Victorino Carol Levinson William Whalen Xiaolin Wang Jennifer Cunningham Olga Vasilenko Maria Burgos Florez Somia P. Hickman Iris Pittman Lam Le Brenda Larkin Charla Andrews Preeti Apte Renunda Hicks Cora Trelles Cartagena Pernell Williams Catina Boyd Michelle Conan-Cibotti Judy Stein Florence Kaltovich Hope DeCederfelt Stacey McAdams Phyllis Renehan Wilbur Chen Nancy Greenberg Nancy Wymer Linda Wadsworth Melissa Billington Toni Robinson Colleen Boyce Faith Pa'ahana Brown Lisa Chrisley Alyson Kwon Prashant Patel Panagoita Kominou Brenda Dorsey Staci Eddington Shinyi Telscher Myoughee Lee Regina Mosely April Ross Geoffrey Ford Briyana Domjahn Jianguo Xu Allison Beck Rebecca Fineman Shiela Heeke Jean M. Winter Shashi Nagar Colleen F. Kelley Mark J. Mulligan Sarah H. Plummer Pamela Costner Kathryn L. Zephir Joseph P. Casazza Abidemi Ola Milalynn Victorino Carol Levinson William Whalen Xiaolin Wang Jennifer Cunningham

The Zika virus epidemic and associated congenital infections have prompted rapid vaccine development. We assessed two new DNA vaccines expressing premembrane envelope structural proteins.We did phase 1, randomised, open-label trials involving healthy adult volunteers. VRC 319 trial, done in three centres, plasmid VRC5288 (Zika Japanese encephalitis chimera), the 320, one centre, VRC5283 (wild-type virus). Eligible participants were aged 18-35 years VRC19 18-50 320. Participants randomly...

10.1016/s0140-6736(17)33105-7 article EN other-oa The Lancet 2017-12-05

Background The reasons for black/white disparities in HIV epidemics among men who have sex with puzzled researchers decades. Understanding these requires looking beyond individual-level behavioral risk to a more comprehensive framework. Methods and Findings From July 2010-Decemeber 2012, 803 (454 black, 349 white) were recruited through venue-based online sampling; consenting provided STI testing, completed survey partner inventory, place of residence geocoding. prevalence was higher black...

10.1371/journal.pone.0090514 article EN cc-by PLoS ONE 2014-03-07

Coronavirus disease 2019 (COVID-19) vaccines have begun to be distributed across the United States and offered initially priority groups including health care personnel persons living in long-term facilities. Guidance regarding whether pregnant should receive a COVID-19 vaccine is needed. Because were excluded from initial phase 3 clinical trials of vaccines, limited data are available on their efficacy safety during pregnancy. After developmental reproductive toxicology studies completed,...

10.1097/aog.0000000000004290 article EN Obstetrics and Gynecology 2020-12-23

Abstract Background In the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and protection. Methods Through case-cohort sampling, participants selected for measurement four serum markers at Day 1 (first dose), 29 (second 57: IgG binding antibodies (bAbs) to Spike, bAbs Spike receptor-binding domain (RBD), 50% 80% inhibitory dilution...

10.1101/2021.08.09.21261290 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2021-08-10
Cameron R. Wolfe Kay M Tomashek Thomas F. Patterson Carlos A. Gómez Vincent C. Marconi and 95 more Mamta K. Jain Otto O. Yang Catharine I. Paules Guillermo M. Ruiz Palacios Robert Grossberg Michelle Harkins Richard A. Mularski Nathaniel Erdmann Uriel Sandkovsky Eyad Almasri Justino Regalado Pineda Alexandra W. Dretler Diego López de Castilla Angela R. Branche Pauline K. Park Aneesh K. Mehta William R. Short Susan McLellan Susan Kline Nicole M. Iovine Hana M. El Sahly Sarah B. Doernberg Myoung‐don Oh Nikhil Huprikar Elizabeth Hohmann Colleen F. Kelley Mark Holodniy Eu Suk Kim Daniel A. Sweeney Robert W. Finberg Kevin A. Grimes Ryan C. Maves Emily R. Ko John J. Engemann Barbara S. Taylor Philip O. Ponce LuAnn Larson Dante P. Melendez Allan Seibert Nadine Rouphael Joslyn K. Strebe Jesse L. Clark Kathleen G. Julian Alfredo Ponce‐de‐León Anabela Cardoso Stephanie de Bono Robert L. Atmar Anuradha Ganesan Jennifer L Ferreira Michelle Green Mat Makowski Tyler Bonnett Tatiana Beresnev Varduhi Ghazaryan Walla Dempsey Seema Nayak Lori E. Dodd John H. Beigel André C. Kalil Lana Wahid Emmanuel B. Walter Akhila G. Belur Grace R. Dreyer Jan E. Patterson Jason E. Bowling Danielle O. Dixon Angela Hewlett Robert Odrobina Jakrapun Pupaibool Satish Mocherla Suzana Lazarte Meilani Cayabyab Rezhan H. Hussein Reshma Golamari Kaleigh L. Krill Sandra Rajme‐López Paul Riska Barry S. Zingman Grégory Mertz Néstor Sosa Paul Goepfert Mezgebe Berhe Emma Dishner Mohamed Fayed Kinsley Hubel José Arturo Martinez-Orozco Nora Bautista Felix Sammy T. Elmor Amer Ryan Bechnak Youssef Saklawi Jason W. Van Winkle Diego F. Zea Maryrose Laguio‐Vila Edward E. Walsh Ann R. Falsey

10.1016/s2213-2600(22)00088-1 article EN The Lancet Respiratory Medicine 2022-05-23

BackgroundTwice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy preexposure prophylaxis (PrEP) men, transgender women, and gender-nonbinary persons is unclear.MethodsIn this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants a 2:1 ratio receive every 26 weeks or daily oral emtricitabine–tenofovir disoproxil fumarate (F/TDF). primary analysis compared the incidence...

10.1056/nejmoa2411858 article EN New England Journal of Medicine 2024-11-27

Background: HIV incidence among US young, black men who have sex with (YBMSM) is high, and structural barriers (eg lack of health insurance) may limit access to Pre-exposure prophylaxis (PrEP). Research studies conducted YBMSM must ensure the best available prevention methods, including PrEP. Methods: We implemented an optional, nonincentivized PrEP program in addition standard services a prospective, observational cohort HIV-negative Atlanta, GA. Provider visits laboratory costs were...

10.1097/qai.0000000000001497 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2017-07-14

Abstract Background Human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) has great potential to reduce HIV incidence among young black men who have sex with (YBMSM); however, initiation and persistence for this group remain low. We sought understand the patterns predictors of PrEP uptake discontinuation YBMSM in Atlanta, Georgia. Methods was offered all participants a prospective cohort aged 18–29 years not living HIV. Time uptake, first discontinuation, final were assessed...

10.1093/cid/ciz894 article EN Clinical Infectious Diseases 2019-09-06

Recruiting valid samples of men who have sex with (MSM) is a key component the US human immunodeficiency virus (HIV) surveillance and research studies seeking to improve HIV prevention for MSM. Social media, such as Facebook, may present an opportunity reach broad MSM, but extent which those are comparable recruited from venue-based, time-space sampling (VBTS) unknown.The objective this study was assess comparability MSM via VBTS Facebook.HIV-negative HIV-positive black white were June 2010...

10.2196/resprot.3342 article EN cc-by JMIR Research Protocols 2014-07-17

The response in the United States to coronavirus disease (COVID-19) pandemic has been hampered by a lack of aggressive testing for infection. Testing severe acute respiratory syndrome 2 (SARS-CoV-2) is cornerstone an effective public health response. However, efforts test have limited reagents, limitations availability swabs used collection nasopharyngeal swab (NPS) specimens, personal protective equipment (PPE) care providers collecting NPS and viral transport media transporting specimens....

10.2196/19054 article EN cc-by JMIR Public Health and Surveillance 2020-04-19
Zelalem Temesgen Charles D. Burger Jason Baker Christopher Polk Claudia R. Libertin and 95 more Colleen F. Kelley Vincent C. Marconi Robert Orenstein Victoria M. Catterson William S. Aronstein Cameron Durrant Dale Chappell Omar Ahmed Gabrielle Chappell Andrew D. Badley Meghan Lewis Linda Sher Michael E. Bowdish Noah Wald‐Dickler Subarna Biswas L.C.W. Lam Khang Chung Ngoc Vo R Poblete May M. Lee Douglass Hutcheon Roberto L. Patron John Gharbin Caitlin A. Moran Sheetal Kandiah Valeria D. Cantos Paulina A. Rebolledo Carlos del Río Jeffrey L. Lennox Carmen Polito Anandi N. Sheth Anup Patel Homero Paniagua Seife Yohannes Alpesh Amin Richard Lee Miki Watanabe Lanny Hsieh Martin Cearras Amay Parikh Jason Sniffen Wilfred Onyia Michael S Boger Lisa Davidson Kiran Gajurel Michael Leonard Lewis McCurdy Nestor Quezada Mindy Sampson Zainab Shahid Stephanie Strollo David Weinrib Sara Zulfigar Cheryl McDonald John Hollingsworth John R. Burk Joshua Berg D Barbaro Andrew C. Miller Lakshmi Sambathkumar Stuart McDonald Obinna Okoye Juan D Pulido Jennifer C. Fulton William B. Gill Richard A. Zuckerman Lionel D. Lewis Chaitanya Mandapakala Matthew K. Robinson Brian S Metzger Maqsood Alam Chrisoula Politis Anne Frosch Linh Ngo Fernando Carvalho Neuenschwander Estêvão Lanna Figueiredo Gualter CanÇado Gustavo Gomes de Araújo Lucas Melo Guimarães Ricardo Sobhie Diaz Natalia Bacellar Celso H. L. Silva Paulo Roberto Abrão Ferreira Marina Andrade Lima Caroline Uber Ghisi Camila Anton Ricardo Albaneze Daniel Wagner de Castro Lima Santos Ana Caroline Coutinho Iglessias Marianna M. Lago Paula Pietrobom Maysa B. Alves Juvencio Furtado Leopoldo Tosi Trevelin Valéria Telles Francini Guerra Correa

10.1016/s2213-2600(21)00494-x article EN other-oa The Lancet Respiratory Medicine 2021-12-02

Data reporting sexually transmitted infection (STI) incidence rates among HIV-negative U.S. men who have sex with (MSM) are lacking. In addition, it is difficult to analyze the effect of STI on HIV acquisition given that sexual risk behaviors confound relationship between bacterial STIs and incident HIV. The InvolveMENt study was a longitudinal cohort black white HIV-negative, active MSM in Atlanta underwent routine screening for completed behavioral questionnaires. Age-adjusted were...

10.1089/aid.2015.0013 article EN AIDS Research and Human Retroviruses 2015-02-26

In Brief Background Studying the heterogeneity and correlates of HIV risk in sexual networks black white men who have sex with (MSM) may help explain racial disparities HIV-infection. Methods Black MSM were recruited as seeds using venue-based time sampling provided data regarding their recent partners. We used chain referral methods to enroll seeds' partners; newly enrolled partners turn on partners, some whom later enrolled. Data about unenrolled obtained from participants also analyzed....

10.1097/olq.0000000000000332 article EN Sexually Transmitted Diseases 2015-08-11
Coming Soon ...